Your browser doesn't support javascript.
loading
Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry.
Zhao, Zhiguo; Wen, Wanqing; Michailidou, Kyriaki; Bolla, Manjeet K; Wang, Qin; Zhang, Ben; Long, Jirong; Shu, Xiao-Ou; Schmidt, Marjanka K; Milne, Roger L; García-Closas, Montserrat; Chang-Claude, Jenny; Lindstrom, Sara; Bojesen, Stig E; Ahsan, Habibul; Aittomäki, Kristiina; Andrulis, Irene L; Anton-Culver, Hoda; Arndt, Volker; Beckmann, Matthias W; Beeghly-Fadiel, Alicia; Benitez, Javier; Blomqvist, Carl; Bogdanova, Natalia V; Børresen-Dale, Anne-Lise; Brand, Judith; Brauch, Hiltrud; Brenner, Hermann; Burwinkel, Barbara; Cai, Qiuyin; Casey, Graham; Chenevix-Trench, Georgia; Couch, Fergus J; Cox, Angela; Cross, Simon S; Czene, Kamila; Dörk, Thilo; Dumont, Martine; Fasching, Peter A; Figueroa, Jonine; Flesch-Janys, Dieter; Fletcher, Olivia; Flyger, Henrik; Fostira, Florentia; Gammon, Marilie; Giles, Graham G; Guénel, Pascal; Haiman, Christopher A; Hamann, Ute; Harrington, Patricia.
Afiliação
  • Zhao Z; Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 2525 West End Avenue, 8th Floor, Nashville, TN, 37203-1738, USA.
  • Wen W; Division of Cancer Biostatistics, Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Michailidou K; Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 2525 West End Avenue, 8th Floor, Nashville, TN, 37203-1738, USA.
  • Bolla MK; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
  • Wang Q; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
  • Zhang B; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
  • Long J; Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 2525 West End Avenue, 8th Floor, Nashville, TN, 37203-1738, USA.
  • Shu XO; Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 2525 West End Avenue, 8th Floor, Nashville, TN, 37203-1738, USA.
  • Schmidt MK; Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 2525 West End Avenue, 8th Floor, Nashville, TN, 37203-1738, USA.
  • Milne RL; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • García-Closas M; Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia.
  • Chang-Claude J; Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
  • Lindstrom S; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
  • Bojesen SE; Division of Cancer Studies, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK.
  • Ahsan H; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Aittomäki K; Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany.
  • Andrulis IL; Program in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, MA, USA.
  • Anton-Culver H; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
  • Arndt V; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Beckmann MW; Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Beeghly-Fadiel A; Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Benitez J; Department of Health Studies, The University of Chicago, Chicago, IL, USA.
  • Blomqvist C; Department of Clinical Genetics, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
  • Bogdanova NV; Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada.
  • Børresen-Dale AL; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
  • Brand J; Department of Epidemiology, University of California Irvine, Irvine, CA, USA.
  • Brauch H; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
  • Brenner H; Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Burwinkel B; Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 2525 West End Avenue, 8th Floor, Nashville, TN, 37203-1738, USA.
  • Cai Q; Human Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid, Spain.
  • Casey G; Centro de Investigación en Red de Enfermedades Raras, Valencia, Spain.
  • Chenevix-Trench G; Department of Oncology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
  • Couch FJ; Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
  • Cox A; Department of Genetics, Institute for Cancer Research, Radiumhospitalet, Oslo University Hospital, Oslo, Norway.
  • Cross SS; K.G. Jebsen Center for Breast Cancer Research, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Czene K; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Dörk T; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Dumont M; University of Tübingen, Tübingen, Germany.
  • Fasching PA; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany.
  • Figueroa J; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
  • Flesch-Janys D; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany.
  • Fletcher O; Division of Preventive Oncology, German Cancer Research Center, Heidelberg, Germany.
  • Flyger H; Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Fostira F; Molecular Epidemiology Group, German Cancer Research Center, Heidelberg, Germany.
  • Gammon M; Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 2525 West End Avenue, 8th Floor, Nashville, TN, 37203-1738, USA.
  • Giles GG; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Guénel P; Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Haiman CA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Hamann U; Sheffield Cancer Research, Department of Oncology, University of Sheffield, Sheffield, UK.
  • Harrington P; Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, UK.
Cancer Causes Control ; 27(5): 679-93, 2016 May.
Article em En | MEDLINE | ID: mdl-27053251
PURPOSE: Type 2 diabetes (T2D) has been reported to be associated with an elevated risk of breast cancer. It is unclear, however, whether this association is due to shared genetic factors. METHODS: We constructed a genetic risk score (GRS) using risk variants from 33 known independent T2D susceptibility loci and evaluated its relation to breast cancer risk using the data from two consortia, including 62,328 breast cancer patients and 83,817 controls of European ancestry. Unconditional logistic regression models were used to derive adjusted odds ratios (ORs) and 95 % confidence intervals (CIs) to measure the association of breast cancer risk with T2D GRS or T2D-associated genetic risk variants. Meta-analyses were conducted to obtain summary ORs across all studies. RESULTS: The T2D GRS was not found to be associated with breast cancer risk, overall, by menopausal status, or for estrogen receptor positive or negative breast cancer. Three T2D associated risk variants were individually associated with breast cancer risk after adjustment for multiple comparisons using the Bonferroni method (at p < 0.001), rs9939609 (FTO) (OR 0.94, 95 % CI = 0.92-0.95, p = 4.13E-13), rs7903146 (TCF7L2) (OR 1.04, 95 % CI = 1.02-1.06, p = 1.26E-05), and rs8042680 (PRC1) (OR 0.97, 95 % CI = 0.95-0.99, p = 8.05E-04). CONCLUSIONS: We have shown that several genetic risk variants were associated with the risk of both T2D and breast cancer. However, overall genetic susceptibility to T2D may not be related to breast cancer risk.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Cancer Causes Control Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Cancer Causes Control Ano de publicação: 2016 Tipo de documento: Article